Phenasen 10 mg/10 ml Concentrated solution for infusion)
PDF Leaflet Revision Date: 06 February 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Induction and consolidation treatment for acute promyelocytic leukaemia.
Dosage (summary)
0.15 mg/kg/day IV until hematological CR or max 60 days; consolidation 0.15 mg/kg/day 5 days/week.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Embryotoxic and teratogenic; contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- QT prolonging medications
- Hepatotoxic medications
Contraindications
- Hypersensitivity to arsenic trioxide
- Heart block
- Congestive cardiac failure
Common side effects
- Leukocytosis
- Hepatotoxicity
- Peripheral neuropathy
- QT prolongation
Counselling Points
- Monitor for signs of APL differentiation syndrome
- Use effective contraception
- Avoid QT prolonging drugs
Serious warnings
- APL differentiation syndrome
- Risk of torsade de pointes
- Potential for sudden death
On This Page
Loading package insert…
Medinsert AI
Hello! I am Medinsert Ai. What would you like to know about this professional information leaftleft?
